ResMed Inc. (RMD) Financial Statements

Income statement

Metric	TTM	2026	2025	2024	2023
Revenue
Total Revenue	5.7B	5.7B	5.1B	4.7B	4.2B
Cost of Revenue	2.2B	2.2B	2.1B	2.0B	1.9B
Gross Profit	3.5B	3.5B	3.1B	2.7B	2.4B
Operating Expenses
R&D Expense	378.3M	378.3M	331.3M	307.5M	287.6M
SG&A Expense	817.4M	817.4M	991.0M	917.1M	874.0M
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	369.4M	369.4M	47.3M	110.7M	62.1M
Total Operating Expenses	1.6B	1.6B	1.4B	1.3B	1.2B
Cost and Expenses	3.8B	3.8B	3.5B	3.4B	3.1B
Operating Income (EBIT)	1.9B	1.9B	1.7B	1.3B	1.1B
Non-Operating
Interest Income	20.9M	—	—	—	—
Interest Expense	29.0M	29.0M	12.6M	45.7M	47.4M
Net Interest Income	(8.1M)	(29.0M)	(12.6M)	(45.7M)	(47.4M)
Other Non-Op Income/Expense	26.8M	26.8M	(7.8M)	(55.1M)	(30.2M)
Non-Operating Income (excl Interest)	(55.8M)	(55.8M)	9.8M	9.4M	(30.4M)
EBT (Pre-Tax Income)	1.9B	1.9B	1.7B	1.3B	1.1B
Income Tax Expense	396.1M	396.1M	276.8M	243.8M	204.1M
Bottom Line
Net Income	1.5B	1.5B	1.4B	1.0B	897.6M
Earnings from Cont. Ops	1.5B	1.5B	1.4B	1.0B	897.6M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	1.5B	1.5B	1.4B	1.0B	897.6M
Per Share
Basic EPS	$10.44	$10.44	$9.55	$6.94	$6.12
Diluted EPS	$10.40	$10.40	$9.51	$6.92	$6.09
Revenue Per Share	$39.07	$39.07	$35.08	$31.87	$28.77
Shares
Basic Shares Outstanding	144.7M	144.7M	146.7M	147.0M	146.8M
Diluted Shares Outstanding	145.0M	145.0M	147.3M	147.6M	147.5M
Profitability Metrics
EBITDA	2.1B	2.1B	1.9B	1.5B	1.4B
D&A	197.9M	197.9M	235.8M	216.2M	196.5M
EBIT	1.9B	1.9B	1.7B	1.3B	1.2B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026